Smoldering or asymptomatic multiple myeloma may be best described as a state of limbo where the patient has not developed any symptoms of disease and is being observed expectantly. With the advent of novel agents in myeloma therapy, several clinical investigations are underway to determine whether early intervention will help improve survival outcomes in this patient population. Mateos MV et al. report on the first Phase III trial in smoldering multiple myeloma that has shown overall survival benefit. The commentary discusses the study design, key results and potential implications of the study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/17474086.2014.874944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dementia Care Practice.
Alzheimers Dement
December 2024
Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
Aims: The Alzheimer Association (AA) has proposed new diagnostic criteria for Alzheimer's disease (AD) based on biomarkers coinciding with β-amyloidosis onset. However, there are concerns regarding the implications of these criteria.
Methods: We reviewed several perspectives, including disease definition, public health, philosophy, therapeutic, and diagnostic.
Serum B-cell maturation antigen could be a simple and accurate biomarker to identify and prognosticate monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Haematologica
January 2025
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa.
Not available.
View Article and Find Full Text PDFMultiple myeloma-associated non-crystalline proximal tubulopathy and crystalline cast nephropathy: Biochemical and structural features of disease-causing monoclonal kappa light chains.
FASEB J
January 2025
Department of Hematology, Nephrology, and Rheumatology, Graduate School of Medicine, Akita University, Akita, Japan.
Various tubular diseases in patients with multiple myeloma (MM) are caused by monoclonal immunoglobulin light chains (LCs). However, the physicochemical characteristics of the disease-causing LCs contributing to the onset of MM-associated tubular diseases remain unclear. We herein report a rare case of MM-associated combined tubulopathies: non-crystalline light chain proximal tubulopathy (LCPT) and crystalline light chain cast nephropathy (LCCN).
View Article and Find Full Text PDFEsophageal Adenocarcinoma Presenting With Hypercalcemia.
ACG Case Rep J
January 2025
The University of Toledo College of Medicine and Life Sciences, Toledo, OH.
Hypercalcemia is an identified complication of several malignancies and can cause significant adverse events. It is usually associated with cancers of the breast, lung (especially squamous cell), renal cell carcinoma, and multiple myeloma. Here, we present a rare case of esophageal adenocarcinoma presenting with hypercalcemia.
View Article and Find Full Text PDFParkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T-Cell Therapy.
Mov Disord Clin Pract
January 2025
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Dvision of Neurology, Toronto Western Hospital, UHN, Krembil Brain Institute, University of Toronto, Toronto, Ontario, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!